Latest post
Pravin Dugel, M.D.: “Biological signal for efficacy of THR-149”
“As an investigator of THR-149, I was encouraged to see the results from its clinical phase 1 trial", Pravin Dugel, M.D., says.
back of the eye diseases, science community,
Phase 1 trial showed THR-149 is a highly potent plasma kallikrein inhibitor to treat DME
In 2019, Oxurion announced positive topline data for the compound THR-149, a highly potent plasma kallikrein inhibitor to treat diabetic macular edema (DME).
science community
A strategic focus for Oxurion: researching and developing non-VEGF pathways
Jean Feyen, PhD., Chief Scientific Officer, and Andy De Deene, M.D., Global Head of Development, explain why Oxurion decided to focus on non-VEGF pathways.